Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.
Gronchi A, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, Mariani L, Valagussa P, Miceli R, Stacchiotti S, Dei Tos AP, De Paoli A, Longhi A, Poveda A, Quagliuolo V, Comandone A, Casali PG, Picci P. Gronchi A, et al. Among authors: verderio p. J Clin Oncol. 2012 Mar 10;30(8):850-6. doi: 10.1200/JCO.2011.37.7218. Epub 2012 Feb 6. J Clin Oncol. 2012. PMID: 22312103 Clinical Trial.
Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals.
Gatti L, Sevko A, De Cesare M, Arrighetti N, Manenti G, Ciusani E, Verderio P, Ciniselli CM, Cominetti D, Carenini N, Corna E, Zaffaroni N, Rodolfo M, Rivoltini L, Umansky V, Perego P. Gatti L, et al. Among authors: verderio p. Oncotarget. 2014 Jun 30;5(12):4516-28. doi: 10.18632/oncotarget.2065. Oncotarget. 2014. PMID: 24980831 Free PMC article.
Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies.
Cona MS, Lecchi M, Cresta S, Damian S, Del Vecchio M, Necchi A, Poggi MM, Raggi D, Randon G, Ratta R, Signorelli D, Vernieri C, de Braud F, Verderio P, Di Nicola M. Cona MS, et al. Among authors: verderio p. Cancers (Basel). 2019 Feb 14;11(2):223. doi: 10.3390/cancers11020223. Cancers (Basel). 2019. PMID: 30769874 Free PMC article.
Plasma miRNA-based signatures in CRC screening programs.
Zanutto S, Ciniselli CM, Belfiore A, Lecchi M, Masci E, Delconte G, Primignani M, Tosetti G, Dal Fante M, Fazzini L, Airoldi A, Vangeli M, Turpini F, Rubis Passoni GG, Viaggi P, Arena M, Motta RIO, Cantù AM, Crosta C, De Roberto G, Iannuzzi F, Cassinotti A, Dall'Olio V, Tizzoni L, Sozzi G, Meroni E, Bisanti L, Pierotti MA, Verderio P, Gariboldi M. Zanutto S, et al. Among authors: verderio p. Int J Cancer. 2020 Feb 15;146(4):1164-1173. doi: 10.1002/ijc.32573. Epub 2019 Aug 5. Int J Cancer. 2020. PMID: 31304978 Free article.
Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.
Di Cosimo S, Appierto V, Pizzamiglio S, Silvestri M, Baselga J, Piccart M, Huober J, Izquierdo M, de la Pena L, Hilbers FS, de Azambuja E, Untch M, Pusztai L, Pritchard K, Nuciforo P, Vincent-Salomon A, Symmans F, Apolone G, de Braud FG, Iorio MV, Verderio P, Daidone MG. Di Cosimo S, et al. Among authors: verderio p. Int J Mol Sci. 2020 Feb 18;21(4):1386. doi: 10.3390/ijms21041386. Int J Mol Sci. 2020. PMID: 32085669 Free PMC article. Clinical Trial.
A combination of extracellular matrix- and interferon-associated signatures identifies high-grade breast cancers with poor prognosis.
Lecchi M, Verderio P, Cappelletti V, De Santis F, Paolini B, Monica M, Sangaletti S, Pupa SM, Iorio MV, Bianchi G, Gennaro M, Fucà G, De Braud F, Tagliabue E, Di Nicola M. Lecchi M, et al. Among authors: verderio p. Mol Oncol. 2021 May;15(5):1345-1357. doi: 10.1002/1878-0261.12912. Epub 2021 Feb 19. Mol Oncol. 2021. PMID: 33523584 Free PMC article.
191 results